KR20040033616A - 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 - Google Patents
파일로리 및 리스테리아 모노사이토진의 생육을 억제하는항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 Download PDFInfo
- Publication number
- KR20040033616A KR20040033616A KR1020020062825A KR20020062825A KR20040033616A KR 20040033616 A KR20040033616 A KR 20040033616A KR 1020020062825 A KR1020020062825 A KR 1020020062825A KR 20020062825 A KR20020062825 A KR 20020062825A KR 20040033616 A KR20040033616 A KR 20040033616A
- Authority
- KR
- South Korea
- Prior art keywords
- antimicrobial
- pediococcus pentosaceus
- helicobacter pylori
- lactic acid
- cbt
- Prior art date
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 101
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 49
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 40
- 241000191996 Pediococcus pentosaceus Species 0.000 title claims abstract description 29
- 239000000463 material Substances 0.000 title claims abstract description 24
- 241000186779 Listeria monocytogenes Species 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 21
- 239000003814 drug Substances 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 13
- 235000013376 functional food Nutrition 0.000 title description 10
- 230000008569 process Effects 0.000 title description 4
- 230000000452 restraining effect Effects 0.000 title 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 7
- 239000008103 glucose Substances 0.000 claims abstract description 7
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 6
- 239000012138 yeast extract Substances 0.000 claims abstract description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 5
- 239000011702 manganese sulphate Substances 0.000 claims abstract description 5
- 235000007079 manganese sulphate Nutrition 0.000 claims abstract description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 5
- 235000013372 meat Nutrition 0.000 claims abstract description 5
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims abstract description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 4
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 4
- 239000001632 sodium acetate Substances 0.000 claims abstract description 4
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 4
- 239000011780 sodium chloride Substances 0.000 claims abstract description 4
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 3
- 230000001954 sterilising effect Effects 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 106
- 239000004310 lactic acid Substances 0.000 claims description 53
- 235000014655 lactic acid Nutrition 0.000 claims description 53
- 241000894006 Bacteria Species 0.000 claims description 43
- 239000011149 active material Substances 0.000 claims description 28
- 239000004599 antimicrobial Substances 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 23
- 238000000855 fermentation Methods 0.000 claims description 22
- 230000000844 anti-bacterial effect Effects 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 241000186781 Listeria Species 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 230000007717 exclusion Effects 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000009036 growth inhibition Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 150000008040 ionic compounds Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 34
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000003405 preventing effect Effects 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 5
- 229940099596 manganese sulfate Drugs 0.000 abstract description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 abstract description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 208000007882 Gastritis Diseases 0.000 description 12
- 235000013351 cheese Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010016952 Food poisoning Diseases 0.000 description 7
- 208000019331 Foodborne disease Diseases 0.000 description 7
- 230000002265 prevention Effects 0.000 description 6
- 241000192001 Pediococcus Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000019249 food preservative Nutrition 0.000 description 3
- 239000005452 food preservative Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- 238000007900 DNA-DNA hybridization Methods 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 240000002129 Malva sylvestris Species 0.000 description 2
- 235000006770 Malva sylvestris Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000186191 Pediococcus inopinatus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- IZSRJDGCGRAUAR-MROZADKFSA-M 5-dehydro-D-gluconate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IZSRJDGCGRAUAR-MROZADKFSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241001608909 Leuconostoc gelidum subsp. gelidum KCTC 3527 Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-OUBTZVSYSA-N Urea-13C Chemical compound N[13C](N)=O XSQUKJJJFZCRTK-OUBTZVSYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000412433 Weissella hanii Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940003630 [13c] urea Drugs 0.000 description 1
- ITLVJEYRPIYSOW-UHFFFAOYSA-N [K].[K].[K] Chemical compound [K].[K].[K] ITLVJEYRPIYSOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- MKSMEGFVJFHTAL-UHFFFAOYSA-L dipotassium;diformate Chemical compound [K+].[K+].[O-]C=O.[O-]C=O MKSMEGFVJFHTAL-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000012134 rapid urease test Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
순서 | 기질(Substrate) | 결과(Result) |
1 | 글리세롤(Glycerol) | |
2 | 에리스리톨(Erythritol) | |
3 | 디 아라비노즈(D Arabinose) | |
4 | 엘 아라비노즈(L Arabinose) | + |
5 | 리보오즈(Ribose) | + |
6 | 디 자이로즈(D Xylose) | + |
7 | 엘 자이로즈(L Xylose) | |
8 | 아도니톨(Adonitol) | |
9 | 베타 메틸-디 자이로사이드(βmethyl-D Xyloside) | |
10 | 갈락토오즈(Galactose) | + |
11 | 글루코즈(Glucose) | + |
12 | 프럭토즈(Fructose) | + |
13 | 만노즈(Mannose) | + |
14 | 솔보즈(Sorbose) | |
15 | 람노즈(Rhamnose) | |
16 | 듈시톨(Dulsitol) | |
17 | 이노시톨(Inositol) | |
18 | 만니톨(Mannitol) | |
19 | 솔비톨(Sorbitol) | |
20 | 알파-메틸-디 만노사이드(α-Methyl-D Mannoside) | |
21 | 알파-메틸-디 글루시오사이드(α-Methyl-D Glucioside) | |
22 | 엔 아세틸 글로코사민(N Acetyl Glucosamine) | + |
23 | 아미고달린(Amygodalin) | + |
24 | 알부틴(Arbutin) | + |
25 | 에스쿠린(Esculin) | + |
26 | 살리실린(Salicine) | + |
27 | 셀로비오즈(Cellobiose) | + |
28 | 말토오즈(Maltose) | + |
29 | 락토오즈(Lactose) | |
30 | 멜리비오즈(Melibiose) | |
31 | 수크로즈(Sucrose) | + |
32 | 트리할로즈(Trehalose) | + |
33 | 인슐린(Inulin) | |
34 | 멜레지토즈(Melezitose) | |
35 | 라피노즈(Raffinose) | |
36 | 전분(Starch) | |
37 | 글리코겐(Glycogen) | |
38 | 자일리톨(Xylitol) | |
39 | 젠티오비오즈(Gentiobiose) | + |
40 | 디 유라노즈(D Turanose) | |
41 | 디 라익소즈(D Lyxose) | |
42 | 디 타가토즈(D Tagatose) | + |
43 | 디 퓨코즈(D Fucose) | |
44 | 엘 퓨코즈(L Fucose) | |
45 | 디 아라비톨(D Arabitol) | |
46 | 엘 아라비톨(L Arabitol) | |
47 | 글로코네이트(Gluconate) | |
48 | 2 케토글루코네이트(2 Keto Gluconate) | |
49 | 5 케토 글루코네이트(5 Keto Gluconate) |
비교균주의 스트레인(Strain) | 기탁번호(ascceddion No.) | 유사도(%) | 차이개수/비교갯수(nt/nt) |
페디오코커스 펜토사세우스(Pedicoccus pentosaceus) DSM 20336T | AJ305321 | 99.52 | 7/1471 |
페디오코커스 액시딜라티시(Pedicoccus acidilactici) B1104 | AJ305322 | 97.96 | 30/1471 |
페디오코커스 액시디락티시(Pedicoccus acidilactici) DSM 20284T | AJ305320 | 97.89 | 31/1471 |
페디오코커스 이노핀투스(Pedicoccus inopinatus) DSM 20285T | AJ271383 | 94.70 | 78/1471 |
페디오코커스 담노서스(Pedicoccus damnosus) DSM 20331 | AJ318414 | 94.56 | 80/1471 |
락토바실러스 펜토서스(Lactobacillus pentosus) JCM 1558T | D79211 | 92.80 | 105/1458 |
바이셀라 하니(Weissella hanii) IH1012T | AY040669 | 87.14 | 187/1454 |
로이코노스톡 게리둠(Leuconostoc gelidum) NRIC 1778 | AB022921 | 84.13 | 227/1430 |
ng/ul | 200 | 150 | 100 | 75 | 50 | 38 | 25 |
CBT-8 | 58791 | 49561 | 37251 | 31608 | 24899 | 21887 | 19775 |
JC2059 | 33770 | 42167 | 36419 | 30597 | 21326 | 12304 | 7225db |
유사도(%) | 57.40 | 85.08 | 97.76 | 96.8 | 85.65 | 56.21 | 36.53 |
100~50 범위 내에서 유사도 평균 약 93% |
마이크로오르가니즘 인디케이터(microorganism indicator) | AU/ml(Culture broth) |
헬리코박터 파일로리(H.pylori) ATCC 43504 | 1,600 |
리스테리아 이바노이(L. ivanoii) KCTC 3444 | 100 |
리스텔리아 그라비(L. gravy) KCTC 3443 | 3,200 |
리스테리아 세엘리거(L. seeliger) KCTC 3591 | 200 |
리스테리아 벨시메리(L. welshimeri) KCTC 3587 | 800 |
리스테리아 오노큐아(L. innocua) KCTC 3587 | 400 |
리스테리아 모노사이토진(L. monocytogenes) KCTC 3569 | 1,600 |
살모넬라 갈리나룸(S.gallinarum) ATCC 9184 | 200 |
프로피오니박테리움 아크네스(Propionibacterium.acnes) ATCC29399 | 200 |
공 정 | 항균활성 | |
헬리코박터 파일로리균 | 리스테리아 모노사이토진균 | |
16시간 발효원액 | 1,600 Au/ml | 1,600 Au/ml |
균체제거 발효원액 | 1,600 Au/ml | 1,600 Au/ml |
항균물질 농축액 | 16,000 Au/ml | 16,000 Au/ml |
건조분말 | 16,000 Au/ml | 16,000 Au/ml |
실 험 군 | |||||
대조구A | 감염구B | 경구투여후감염시도구C | 감염후치료시도구D | 동시투여구E | |
실험쥐 No. | 5 | 5 ×2 | 5 ×2 | 5 ×2 | 5 ×2 |
감염균(H.파일로리균)투입량 | - | 108cells/0.3 ml | 108cells/0.3 ml | 108cells/0.3 ml | 108cells/0.3 ml |
항균활성물질(상품명"SAFELAC") 투입량 | - | - | 50 Au/0.2 ml | 50 Au/0.2 ml | 50 Au/0.2 ml |
처리내용 | 무처리 | 7일간H.pylori경구투여감염 시도 | 30일간SAFELAC경구투여종료 후7일간H.pylori경구투여감염시도 | H.pylori감염확인 후30일간SAFELAC경구투여 | 30일간SAFELAC경구투여하며,초기 7일간H.pylori경구투여감염시도 |
확인내용 | 대조구 | 감염 확인 | 감염 방지 확인 | 제균 효과 확인 | 감염 방지 확인 |
구 분 | 항체가온도(℃) | |||||
기간(일) | 0 | 30 | 45 | 65 | 80 | |
실험구 A | 1 | 1 | 1.4 | 1 | 1.3 | |
실험구 B | 1 | 3.4 | 4 | 3.6 | 3.2 | |
실험구 C | 1 | 1 | 0.9 | 1 | 0.9 | |
실험구 D | 1 | 4 | 4.1 | 3 | 1.8 | |
실험구 E | 1 | 1 | 1 | 1.3 | 1.25 |
구분 | 온도(℃) | 실험기간(일) | |||||
0 | 3 | 6 | 9 | 12 | |||
프랑스산 치즈 | 대조구1* | 25 | 3.6 ×104 | 3.3 ×104 | 3.9 ×104 | 4.3 ×105 | 5.3 ×106 |
4 | 3.2 ×104 | 3.1 ×104 | 3.6 ×104 | 5.1 ×104 | 4.9 ×104 | ||
실험구1** | 25 | 2.9 ×104 | 6.7 ×103 | 1.4 ×102 | 1.7 ×101 | 1.5 ×101 | |
4 | 2.7 ×104 | 3.5 ×103 | 2.1 ×102 | 4.6 ×101 | 2.4 ×101 | ||
이탈리아산 치즈 | 대조구2* | 25 | 3.5 ×104 | 8.3 ×104 | 9.9 ×105 | 1.2 ×106 | 3.3 ×106 |
4 | 3.3 ×104 | 4.1 ×104 | 4.6 ×104 | 5.8 ×104 | 6.2 ×104 | ||
실험구2** | 25 | 3.9 ×104 | 7.7 ×103 | 1.6 ×102 | 2.9 ×101 | 1.1 ×101 | |
4 | 3.6 ×104 | 7.5 ×103 | 3.2 ×102 | 3.7 ×101 | 1.5 ×101 | ||
(*)은 각 치즈에 대한 리스테리아 모노사이토진을 처리한 대조구이며,(**)는 각 대조구 치즈에 대비하여 항균활성물질(1%(w/v)SAFELAC Solution)을 처리한 실험예이며, 이들 각각의 수치는 CFU의 단위를 가짐.황균물질(SAFLAC)의 활성도(Activity) : 9600 Au/g |
Claims (7)
- 헬리코박터 파일로리균에 대한 생육 억제능과 리스테리아 모노사이토진균에 대한 생육 억제능을 갖는 항균활성물질을 생산하는 것을 특징으로 하는 페디오코커스 펜토사세우스(Pediococcus pentosaceus) CBT-8인 유산균주(균주기탁번호 KCTC 제10297BP호).
- 페디오코커스 펜토사세우스(Pediococcus pentosaceus) CBT-8인 유산균주를 이용하여 헬리코박터 파일로리균과 리스테리아 모노사이토진균 모두에 항균활성도를 갖는 항균활성물질을 제조하는 방법에 있어서,(a) 페디오코커스 펜토사세우스(Pediococcus pentosaceus) CBT-8인 유산균주를 준비하는 단계;(b) 상기 준비된 유산균에 중량대비 3 내지 5 중량%의 포도당, 0.5 내지 1 중량%의 효모추출물, 1 내지 1,5 중량%의 육엑기스, 0.5 내지 1 중량%의 단백질가수분해물, 0.01 내지 0.1 중량%의 암모늄 시트레이트, 소듐 아세테이트, 디포타슘포스테이트, 마그네슘 셀페이트, 망간 셀페이트, 소듐 클로라이드 중 선택된 하나 이상의 이온결합성화합물을 첨가하여 물에 용해시키는 단계;(c) 상기 첨가물이 포함된 수용액을 살균하는 단계; 및(d) 상기 살균된 수용액에 상기 (a) 단계에서 준비된 유산균주를 투입하고 혐기적 발효관에서 배양하는 단계;를 포함하여 진행하는 것을 특징으로 하는 항균물질 제조방법.
- 제4항에 있어서,상기 (d)단계 이후에, 상기 제조된 항균물질에 대해 고속원심분리 또는 여과장치를 이용하여 농축하는 단계를 더 포함하여 진행하는 것을 특징으로 하는 항균물질 제조방법.
- 제5항에 있어서,상기 여과장치를 이용하여 농축하는 단계는, 제1여과단계에서는 최대배제분자량을 초과하는 물질을 제거하고, 제2여과단계로 최소배제분자량 미만의 물질을 연속적으로 제거하여 소정 범위의 분자량을 갖는 항균물질만을 농축하는 2단 여과방법으로 수행하는 것을 특징으로 하는 항균물질 제조방법.
- 제5항에 있어서,상기 농축단계진행 결과물인 항균물질 농축액에 대해 동결건조방식 또는 분사식 유동층 건조방법에 따라 건조시키는 단계를 더 포함하여 진행하는 것을 특징으로 하는 항균물질 제조방법.
- 식품에 페디오코커스 펜토사세우스(Pediococcus pentosaceus) CBT-8인 유산균주로부터 생산되는 헬리코박터 파일로리균 및 리스테리아 모노사이토진에 대한항균특성을 갖는 항균물질을 첨가하는 것을 특징으로 항균물질 이용방법.
- 의약품에 페디오코커스 펜토사세우스(Pediococcus pentosaceus) CBT-8인 유산균주로부터 생산되는 헬리코박터 파일로리균 및 리스테리아 모노사이토진에 대한 항균특성을 갖는 항균물질을 첨가하는 것을 특징으로 항균물질 이용방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0062825A KR100483369B1 (ko) | 2002-10-15 | 2002-10-15 | 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는 항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을 갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 |
JP2003354432A JP3810403B2 (ja) | 2002-10-15 | 2003-10-14 | ヘリコバクターピロリ(Helicobacterpylori)及びリステリアモノサイトゲネス(Listeriamonocytogenes)の生育を抑制する抗菌活性物質を生産するペディオコッカスペントサセウス(Pediococcuspentosaceus)CBT−8と命名される乳酸菌株、これを利用した抗菌特性を持つ抗菌物質製造方法、並びに生菌剤抗菌物質を機能性食品及び医薬品に利用する方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0062825A KR100483369B1 (ko) | 2002-10-15 | 2002-10-15 | 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는 항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을 갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040033616A true KR20040033616A (ko) | 2004-04-28 |
KR100483369B1 KR100483369B1 (ko) | 2005-04-15 |
Family
ID=32464415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0062825A KR100483369B1 (ko) | 2002-10-15 | 2002-10-15 | 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는 항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을 갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP3810403B2 (ko) |
KR (1) | KR100483369B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332316A (zh) * | 2021-06-29 | 2021-09-03 | 山东沐曦生物科技有限公司 | 抑制幽门螺杆菌的组合物 |
CN115851551A (zh) * | 2022-12-29 | 2023-03-28 | 广西爱生生命科技有限公司 | 一株具有抗幽门螺杆菌作用的戊糖片球菌a21358及其应用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4817323B2 (ja) * | 2004-07-29 | 2011-11-16 | 京都府 | 植物病害防除剤および防除方法 |
KR100627428B1 (ko) * | 2006-05-10 | 2006-09-22 | 이석태 | 미생물 오염을 방지하는 페디오코커스 펜토사세우스 st-01 및 그의 제조방법 |
CN103704741A (zh) * | 2014-01-03 | 2014-04-09 | 扬州大学 | 一种高密度鹅肉香肠用发酵剂的培养方法 |
KR101611829B1 (ko) | 2015-06-08 | 2016-04-14 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 페디오코커스 펜토사세우스 cbt sl4 균주 및 이를 포함하는 조성물 |
KR101611830B1 (ko) * | 2015-06-08 | 2016-04-27 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 비피도박테리움 브레베 cbt br3 균주 및 이를 포함하는 조성물 |
KR101915949B1 (ko) * | 2018-01-09 | 2018-11-07 | 주식회사 쎌바이오텍 | 유전자 발현 카세트 및 그를 포함하는 발현벡터 |
-
2002
- 2002-10-15 KR KR10-2002-0062825A patent/KR100483369B1/ko active IP Right Grant
-
2003
- 2003-10-14 JP JP2003354432A patent/JP3810403B2/ja not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332316A (zh) * | 2021-06-29 | 2021-09-03 | 山东沐曦生物科技有限公司 | 抑制幽门螺杆菌的组合物 |
CN115851551A (zh) * | 2022-12-29 | 2023-03-28 | 广西爱生生命科技有限公司 | 一株具有抗幽门螺杆菌作用的戊糖片球菌a21358及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2004135669A (ja) | 2004-05-13 |
KR100483369B1 (ko) | 2005-04-15 |
JP3810403B2 (ja) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101750468B1 (ko) | 락토바실러스 퍼멘툼 mg901 또는 락토바실러스 플란타룸 mg989를 포함하는 조성물 | |
DK2647694T3 (en) | BIOMASS OF DEATH LACTOBACILLUS FOR ANTIMICROBIAL USE AND PROCEDURE FOR PREPARING THEREOF | |
KR101772870B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 | |
US9457054B2 (en) | Method for using a Bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions | |
HUE025851T2 (en) | Mammalian milk microorganisms, preparations containing them, and their use in the treatment of pneumonia | |
KR102052056B1 (ko) | 항균 활성을 나타내는 락토바실러스 플란타룸 균주 및 이의 용도 | |
CN105308179B (zh) | 噬菌体、包括其的组成物及其应用 | |
KR102391832B1 (ko) | 클로스트리디오이데스 디피실 억제용 유산균 복합 균주 및 이를 포함하는 장염증 예방, 치료 또는 개선용 조성물 | |
JP3648233B2 (ja) | 飼料組成物 | |
KR102052047B1 (ko) | 항균 활성을 나타내는 페디오코커스 펜토사세우스 균주 및 이의 용도 | |
KR101959730B1 (ko) | 항균 활성을 갖는 스타필로코커스 갈리나럼 균주 및 이의 항균 용도 | |
CN107854495B (zh) | 凝结芽孢杆菌在制备降低血尿酸制剂中的应用 | |
KR100483369B1 (ko) | 파일로리 및 리스테리아 모노사이토진의 생육을 억제하는 항균활성물질을 생산하는 페디오코커스 펜토사세우스cbt-8로 명명되는 유산균주, 이를 이용한 항균특성을 갖는 항균물질 제조 방법 및 그 제조된 항균물질 기능성식품 및 의약품에 이용하는 방법 | |
JP3017493B1 (ja) | 自己免疫疾患予防組成物 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
KR101772875B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 | |
JP2004135669A6 (ja) | ヘリコバクターピロリ(Helicobacterpylori)及びリステリアモノサイトゲネス(Listeriamonocytogenes)の生育を抑制する抗菌活性物質を生産するペディオコッカスペントサセウス(Pediococcuspentosaceus)CBT−8と命名される乳酸菌株、これを利用した抗菌特性を持つ抗菌物質製造方法、並びに生菌剤抗菌物質を機能性食品及び医薬品に利用する方法 | |
JP4509250B2 (ja) | Helicobacterpylori除菌性医薬品 | |
KR102452957B1 (ko) | 프로바이오틱스 균주를 유효성분으로 포함하는 클로스트리디오이데스 디피실레 감염을 예방 또는 치료하기 위한 조성물 | |
KR100646938B1 (ko) | 헬리코박터 필로리의 정착과 생육 활성을 저해하는락토바실루스 람노서스 아이디씨씨 3201 | |
Wagner et al. | Potential hazards of probiotic bacteria for immunodeficient patients | |
KR101772872B1 (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 및 이의 용도 | |
KR102463809B1 (ko) | 클로스트리디오이데스 디피실레에 항균 활성을 갖는 락토바실러스 파라카세이 WiKim0110 균주 및 이를 포함하는 조성물 | |
KR102244732B1 (ko) | 프로바이오틱 초산균인 아세토박터 파스테리아누스 mglv 및 이의 면역조절 효과 | |
Guerra | A review on some chemical engineering and microbiological aspects considered in the production of highly concentrated probiotic cultures and bacteriocins by lactococci and lactobacilli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130225 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140211 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150211 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160405 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170110 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180110 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20200302 Year of fee payment: 16 |